✦ LIBER ✦

Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer

✍ Scribed by B.C. Pestalozzi; A. Vass; H. Adam; D.H. Horber; R.A. Schwendener; Chr. Sauter

Book ID: 116166196
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 137 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)00010-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CMF and mitoxantrone in elderly patients

CMF and mitoxantrone in elderly patients with advanced breast cancer. A randomized phase II study

✍ M.A. Nooij; E. Steenland; L.V.A.M. Beex; B. van de Bos; L. Ruiter; J.C.J.M. Haes 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Phase II evaluation of mitoxantrone plus

Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer

✍ Joshua O. Atiba; Stephanie J. Green; Harry E. Hynes; C. Kent Osborne; Thomas P. 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 266 KB

Mitoxantrone/prednimustine combination t

Mitoxantrone/prednimustine combination therapy in advanced breast cancer—A phase II study

✍ H. Schmid; C. Manegold; M. Kaufmann; F. Kubli 📂 Article 📅 1986 🏛 Springer-Verlag 🌐 English ⚖ 133 KB

Dose intensification of mitoxantrone in

Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study

✍ Francesco Di Costanzo; Andrea Sdrobolini; Luigi Manzione; Domenico Bilancia; Lui 📂 Article 📅 1999 🏛 Springer US 🌐 English ⚖ 42 KB

Phase II study of mitoxantrone, 5-fluoro

Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients

✍ Serafina Mammoliti; Laura Merlini; Cinzia Caroti; Luigi Gallo 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 314 KB

Phase II studies of mitoxantrone in pati

Phase II studies of mitoxantrone in patients with primary liver cancer

✍ Geoffrey Falkson; Barend Johannes Coetzer 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 147 KB

Forty-nine patients with histologically conlirmed primary liver cancer have been entered on phase II trials of mitoxantrone (NovantroneC"~; dihydroxyanthracenedione), at a dose of 14 mg/m 2 every 3 weeks. Among the patients evaluable for toxicity, leukopenia and thrombocytopenia were the most import